% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • bioimmunomabman bioimmunomabman Oct 25, 2013 9:20 AM Flag

    Good call

    It was good to hear John on the call and Dan did a nice job. The positive is, there will be a lot of clinical data over the next year. The P&L numbers look better than expected on an accounting basis, but on a cash flow basis there was really no positive surprise. The difference is the timing between receiving and recognizing cash already received. IMGN is still a value biotech with great upside potential, but not sure today's P&L should have been the catalyst to recognize this fact. Whatever works...

    The ideal body weight concept is interesting. When it was first mentioned, it thought analysts would turn this into this quarterly cc's debacle. Those analysts that are against IMGN will probably try this tactic, but the idea does make some sense.

    Glad to hear questions about the new technology. It's early stage, but could be a very valuable asset for a potential partner.

13.58-0.01(-0.07%)11:13 AMEST